ALLOCYTE™ Advanced
Cellular Bone Matrix

ALLOCYTE™ Advanced Cellular Bone Matrix is a next generation
cellular bone matrix (CBM) containing bone-derived progenitor
cells and conformable bone fibers.

Product Brochure IFU
FORTIFY FLOWABLE™ Extracellular Matrix

Distinguishing Features

  • Handling:

    Bone fibers provide robust and conformable handling. Packaged in an open bore syringe to allow delivery directly from the syringe.

  • Viability:

    Cryopreserved using a DMSO-free cryoprotectant, eliminating the need to rinse and decant the tissue prior to implantation.

  • Growth Factor Preservation:

    ALLOCYTE™ undergoes a novel patented process that preserves the native growth factors from ancillary bone lining cells which are typically removed during traditional CBM processing.
Distinguishing Features

Graft viability post thaw

5 Hours

Thawed in warm saline without decanting in

10 Minutes

Cell viability after one year of storage is

99.55%

of initial viable and active cell count

In vitro, ALLOCYTE™ showed over

6x Higher osteoinductive Potential

than donor matched control.2

allocyte

The Proprietary Processing in ALLOCYTE™
Preserves Native Growth Factors1

  • ALLOCYTE™ undergoes a novel process to remove red blood cells, white blood cells, and adipocytes. Bone progenitor cells remain attached to the tissue and are retained in the implant through implantation.
  • Cell count is performed using a functional assay that not only determines viability of the cells, but also ensures the cells exhibit activity via MTS assay. This increased scrutiny eliminates false positives and inaccurate cell counts.
  • ALLOCYTE’S™ proprietary process results in removal of immunogenic components mitigating concerns for immune response.

References

  • 1. Data on file.
  • 2. Data on file
Doctor

Keep Up With the Latest Developments in Surgical and Wound Care Technology

Sign Up for the Sanara MedTech Mailing List

Most Recent Press Releases

Sanara MedTech Inc. Announces Second Quarter 2022 Earnings Release and Conference Call Dates

August 3, 2022

Sanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition

July 11, 2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

May 17, 2022
All Press Releases
Get In Touch
  • This field is for validation purposes and should be left unchanged.

Logo

1200 Summit Avenue, Suite 414
Fort Worth, TX 76102 | (817) 529-2300

© 2022 All Rights Reserved. Sanara MedTech Inc.